New Delhi, September 2, 2026: In a step towards addressing India’s critical need for organ donors, Mankind Pharma Limited (“Mankind Pharma” or “Mankind”), one of India’s leading pharmaceutical companies, has launched its nationwide public awareness campaign “Angdaan Mahadaan”, with a goal of inspiring 1 crore Indians to pledge for organ donation.
The campaign was launched in the presence of transplant specialists and dignitaries from the National Organ and Tissue Transplant Organisation (NOTTO), who came together to raise public awareness, dispel myths, and highlight the transformative impact of organ donation. Through “Angdaan Mahadaan”, Mankind Pharma aims to create greater awareness, address misconceptions, and motivate millions of Indians to turn awareness into meaningful action.
Thousands of patients are waiting for life-saving organ transplants. For many, an organ transplant is the only chance to survive or live a healthier life. Unfortunately, the demand for organs far exceeds the number of available donors. By choosing to become an organ donor, individuals can offer hope, restore health, and give someone a second chance at life.
Campaign Vision
The initiative seeks to take the conversation around organ donation beyond hospitals and healthcare institutions and into homes, families, and communities across India — encouraging people to make a conscious decision today that could give someone a second chance at life.
The campaign was launched at an Organ Donation Awareness Event hosted by Mankind Pharma, engaging more than 25,000 Mankindians, their families, and extended communities. The event featured sessions on the realities of organ donation, myths and facts surrounding transplantation, and the current organ donation landscape in India.
Expert Participation
The event brought together leading voices in the field:
- Dr. D.S. Ray, Chief Nephrologist and Head, Renal Transplant Programme, R N Tagore International Institute of Cardiac Sciences, Narayana Health, Kolkata.
- Dr. Abhideep Chaudhary, Chairman and HOD, HPB Surgery and Liver Transplantation, BLK-Max Super Speciality Hospital, New Delhi.
- Dr. Kanika Rastogi, National Organ and Tissue Transplant Organisation (NOTTO), New Delhi.
Rajeev Juneja, Vice Chairman and Managing Director, Mankind Pharma Ltd.: “To give is to live beyond yourself. Through Angdaan Mahadaan, we want to inspire people across India to recognise the extraordinary power of a simple decision: the decision to give someone another chance at life. Our ambition is to motivate 1 crore Indians to pledge for organ donation and make this a movement that creates a lasting legacy of hope.”
Call to Action
The campaign encourages every Indian to take a simple but powerful step: pledge to donate organs and inspire others to do the same. The ambition is clear: 1 crore pledges, 1 crore acts of hope, and a nationwide movement to give life.
Indians can register their pledge through the National Organ and Tissue Transplant Organisation (NOTTO) at: 👉 https://notto.mohfw.gov.in/donor-pledge
Through “Angdaan Mahadaan”, Mankind Pharma aims to build a culture where organ donation becomes a conversation in every home and a conscious choice for every individual. The greatest gift we can leave behind is not what we own, but by pledging to become an organ donor today, we can Live Beyond our Life.
Angdaan Mahadaan: Pledge. Inspire. Save Lives.
About Mankind Pharma Limited
Mankind Pharma (BSE: 543904 | NSE: MANKIND) is one of the largest pharmaceutical companies in India, with a strong domestic presence across both pharmaceutical formulations and consumer healthcare.
- Therapeutic Areas: Acute and chronic segments including anti-infectives, cardiovascular, gastrointestinal, antidiabetic, neuro/CNS, gynaecology, VMN, and respiratory.
- Consumer Healthcare: Leading brands in condoms, pregnancy detection, emergency contraceptives, antacid powders, vitamin & mineral supplements, and anti-acne preparations.
- Women’s Health: Strengthened leadership through the acquisition of BSV.
- Distribution Network: 18,500+ professionals, reaching over five lakh doctors across urban and rural markets.
- Manufacturing: 32 facilities producing tablets, capsules, syrups, vials, ampoules, blow-fill-seal, soft and hard gels, eye drops, creams, contraceptives, and OTC products.
- Innovation: 7 dedicated R&D facilities backed by 740+ scientists, driving consistent product innovation.
